January 27, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Zosano Pharma Corp (NASDAQ:ZSAN) shares over potential securities laws violations by Zosano Pharma and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Zosano Pharma Corp (NASDAQ:ZSAN) concerning whether a series of statements by Zosano Pharma Corp regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Fremont, CA based Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Zosano Pharma Corp went public in January 2015 and shares of Zosano Pharma Corp (NASDAQ:ZSAN) grew to as high as $11.67 per share in March 2015. Since then shares of Zosano Pharma Corp (NASDAQ:ZSAN) declined to as low as $2.00 per share on January 20, 2016.